Details for New Drug Application (NDA): 020111
✉ Email this page to a colleague
NDA 020111 describes CHLORHEXIDINE GLUCONATE, which is a drug marketed by Sage Prods, Akorn, Bajaj, Chartwell Rx, Lyne, Pharm Assoc, Xttrium, Becton Dickinson, and Kendall Il, and is included in ten NDAs. It is available from twenty-eight suppliers. There are four patents protecting this drug. Additional details are available on the CHLORHEXIDINE GLUCONATE profile page.
The generic ingredient in CHLORHEXIDINE GLUCONATE is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.
The generic ingredient in CHLORHEXIDINE GLUCONATE is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.
Summary for 020111
| Tradename: | CHLORHEXIDINE GLUCONATE |
| Applicant: | Bajaj |
| Ingredient: | chlorhexidine gluconate |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 020111
| Physiological Effect | Decreased Cell Wall Integrity |
Medical Subject Heading (MeSH) Categories for 020111
Suppliers and Packaging for NDA: 020111
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CHLORHEXIDINE GLUCONATE | chlorhexidine gluconate | SOLUTION;TOPICAL | 020111 | NDA | Bajaj Medical, LLC | 61037-414 | 61037-414-01 | 118 mL in 1 BOTTLE, PLASTIC (61037-414-01) |
| CHLORHEXIDINE GLUCONATE | chlorhexidine gluconate | SOLUTION;TOPICAL | 020111 | NDA | Bajaj Medical, LLC | 61037-414 | 61037-414-02 | 236 mL in 1 BOTTLE, PLASTIC (61037-414-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | SOLUTION;TOPICAL | Strength | 0.75% | ||||
| Approval Date: | Sep 11, 1997 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
